个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Real-world data indicated that neoadjuvant chemotherapy alone was associated with a higher risk of tumor recurrence in high‑risk breast cancer subgroup patients

| 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Li Zhensheng[1,*1] * ; Li Yue[1] ; Liu Yunjiang[2,*2] ; Shang Yuguang[1] ; Zhou Yarong[2] ; Ji Xiaohui[3] ; Han Huina[1] ; Du Kaiye[1] ; Zhang Jun[1] ;
机构： [1]Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050035, P.R. China. [2]Department of Breast Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050035, P.R. China. [3]Department of Ultrasound, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050035, P.R. China.
出处：
DOI： 10.3892/ol.2023.13779
ISSN：

关键词： breast cancer disease‑free survival neoadjuvant chemotherapy adjuvant chemotherapy real‑world data

摘要：
Numerous clinical trials have reported equal effects of tumor control between neoadjuvant chemotherapy (NAC) and adjuvant chemotherapy (AC) in patients with breast cancer (BC). However, this conclusion has not been verified in practice. The present retrospective study evaluated if there were different risk profiles for NAC, AC and their combinative modes on disease-free survival (DFS) in patients with BC using real-world data. All women with primary unilateral Stage I-III BC and first recurrence in 2008-2018 at The Fourth Hospital of Hebei Medical University were retrospectively identified for enrollment. The four modes of chemotherapy administered for primary BC were classified as 'None', 'NAC only', 'NAC+AC' and 'AC only'. One multivariate Cox model was used to estimate the adjusted Hazard Ratio (HR) and P-value. Covariates included age, Easter Cooperative Oncology Group grade, T stage, N stage, pathology, grade, lymphovascular invasion (LVI), BC subtype, number of chemotherapy cycles and other therapies. Amongst 637 patients, who had a mean age of 48.2 years at BC diagnosis and 50.9 years at recurrence, the median DFS by the 'None' (n=27), 'NAC only' (n=47), 'NAC+AC' (n=118) and 'AC only' (n=445) modes were 31.4, 16.6, 22.6 and 28.4 months (P<0.001), respectively. Compared with the 'AC only', adjusted HR (P-value) of the 'None', 'NAC only' and 'NAC+AC' modes on tumor recurrence were 1.182 (0.551), 1.481 (0.037) and 1.102 (0.523), respectively. The adjusted HR of 'NAC only' vs. 'AC only' modes were 1.448 (P=0.157) for locoregional recurrence and 2.675 (P=0.003) for distant recurrence. Stratified analyses further indicated that the 'NAC only' mode was associated with a higher recurrence risk in T3-4, N2-3, LVI-positive, or HER2-negative subgroup patients. In conclusion, NAC alone was associated with a higher risk of tumor recurrence in high-risk BC subgroup patients in real-world data. Patient selection of chemotherapy mode was involved in practice but could not fully explain this finding. The 'inadequate' NAC was highly likely to have accounted for this observation.Copyright: © Li et al.

语种：
外文
WOS：
PubmedID：
中科院分区：
出版当年[2023]版：
大类 | 4 区 医学
小类 | 4 区 肿瘤学
最新[2025]版：
大类 | 4 区 医学
小类 | 4 区 肿瘤学
JCR分区：
出版当年[2023]版：
Q3 ONCOLOGY
最新[2024]版：
Q3 ONCOLOGY

影响因子： 最新[2024版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版] 出版后一年[2024版]

第一作者：
第一作者机构： [1]Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050035, P.R. China. [*1]Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, 169 Tianshan Street, Shijiazhuang, Hebei 050035, P.R. China
通讯作者：
通讯机构： [1]Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050035, P.R. China. [2]Department of Breast Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050035, P.R. China. [*1]Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, 169 Tianshan Street, Shijiazhuang, Hebei 050035, P.R. China [*2]Department of Breast Surgery, The Fourth Hospital of Hebei Medical University, 169 Tianshan Street, Shijiazhuang, Hebei 050035, P.R. China
推荐引用方式(GB/T 7714)：
Li Zhensheng,Li Yue,Liu Yunjiang,et al.Real-world data indicated that neoadjuvant chemotherapy alone was associated with a higher risk of tumor recurrence in high&#x2011;risk breast cancer subgroup patients[J].ONCOLOGY LETTERS.2023,25(5):doi:10.3892/ol.2023.13779.
APA：
Li Zhensheng,Li Yue,Liu Yunjiang,Shang Yuguang,Zhou Yarong...&Zhang Jun.(2023).Real-world data indicated that neoadjuvant chemotherapy alone was associated with a higher risk of tumor recurrence in high&#x2011;risk breast cancer subgroup patients.ONCOLOGY LETTERS,25,(5)
MLA：
Li Zhensheng,et al."Real-world data indicated that neoadjuvant chemotherapy alone was associated with a higher risk of tumor recurrence in high&#x2011;risk breast cancer subgroup patients".ONCOLOGY LETTERS 25..5(2023)

相关文献

[1]The Survival Benefit of Pegylated Liposomal Doxorubicin-Based Neoadjuvant Chemotherapy in the Management of Breast Cancer [2]Neoadjuvant PD-1 blockade combined with chemotherapy for patients with resectable locally advanced esophageal squamous cell carcinoma (ESCC): A real world data analysis [3]A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer [4]Tumor mutation burden and JARID2 gene alteration are associated with short disease-free survival in locally advanced triple-negative breast cancer [5]Full Compliance of Adjuvant Endocrine Therapy Is Associated with Higher Disease-Free Survival in Hormone Receptor-Positive and HER2-Negative Chinese Breast Cancer Patients with First Tumor Recurrence [6]The Effect of the Leptin and Leptin Receptor Expression on the Efficacy of Neoadjuvant Chemotherapy in Breast Cancer [7]ALK Testing in Chinese Advanced NSCLC Patients: A National-Wide Multicenter Prospective Real-World Data Study (The RATICAL Study) [8]Overall survival and disease-free survival prediction in Chinese women with breast cancer aged 70 years or older by using nomograms [9]Multi-center investigation of the clinical and pathological characteristics of inflammatory breast cancer based on Chinese Society of Breast Surgery (CSBrs-007) [10]Survival benefits of adjuvant chemotherapy for patients with residual pathologic disease after neoadjuvant chemotherapy and surgery for locally advanced esophageal squamous cell carcinoma

资源点击量：42329 今日访问量：0 总访问量：1365 更新日期：2025-08-01 建议使用谷歌、火狐浏览器 常见问题

技术支持：重庆聚合科技有限公司 地址：河北省石家庄市健康路12号